FDA Warning Letters
This article was originally published in The Silver Sheet
Executive Summary
Hospira cited for QS reg violations; Dexcom failed to report MDRs to the agency in a timely fashion. Four warning letters listed by FDA from March 18 through April 17.
You may also be interested in...
NANS 2021: Nevro’s HF10 Spinal-Cord Stimulator Succeeds In Two Trials
SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.
Warning Letter Roundup & Recap – 19 January 2021
No device-related warning letters were released by the US FDA the week of 19 January.
Start-Up Spotlight: CorWave Takes Inspiration From Nature To Tackle Heart Failure
Following a €2.5m award from the European Commission’s EIC Accelerator Program, Paris based CorWave has become the first EU company to obtain EIC fund investment. The company is developing a new pulsatile LVAD.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: